---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-026060"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:03:41.140166+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences reports Q2 prelim costs $11.7M; appoints Paul LaViolette as Co-Chairman

## Summary
- GAAP costs and expenses $11.7M for Q2 2024; non-GAAP $9.4M; cash $26.2M as of June 30, excluding $60M rights offering closed July 2024.
- Oversubscribed rights offering generated $60M gross proceeds; warrants could add up to $66M.
- Completed first US soft tissue ablation procedure after FDA clearance; pivotal trial for benign thyroid nodules planned in 2025.
- Received FDA Breakthrough Device Designation for Cardiac Surgery System for AF; first European epicardial ablations completed.
- Appointed Paul LaViolette as Co-Chairman of Board; he brings 40 years medtech experience from Boston Scientific.

## SEC filing metadata
- accession: 0001437749-24-026060
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/0001437749-24-026060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/plse20240614_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-026060
- JSON: https://secwatch.observer/filing/0001437749-24-026060.json
- Plain text: https://secwatch.observer/filing/0001437749-24-026060.txt

## Key facts
- Executive change
  Robert W. Duggan was appointed as Co-Chairman of the Board at PULSE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Co-Chairman of the Board
  source text: the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/0001437749-24-026060-index.htm
- Executive change
  Paul A. LaViolette was elected as Director at PULSE BIOSCIENCES, INC..
  - Action: elected
  - Role: Director
  source text: the Board of Directors of Pulse Biosciences, Inc. (the “Company”) elected Paul A. LaViolette to serve as a member of the Company’s Board of Directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/0001437749-24-026060-index.htm
- Executive change
  Paul A. LaViolette was appointed as Co-Chairman of the Board at PULSE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Co-Chairman of the Board
  source text: the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774924026060/0001437749-24-026060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.